- 1Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary
- 2Research and Development Department, Hycult Biotech, Uden, Netherlands
- 3Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom
- 4Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
- 5Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
- 6Research Group for Immunology and Haematology, Semmelweis University – Eötvös Loránd Research Network (Office for Supported Research Groups), Budapest, Hungary
By Hurler L, Toonen EJM, Kajdácsi E, van Bree B, Brandwijk RJMGE, de Bruin W, Lyons PA, Bergamaschi L, Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, Sinkovits G, Cervenak L, Würzner R and Prohászka Z (2022) Front. Immunol. 13:1039765. doi: 10.3389/fimmu.2022.1039765
In the published article, there was an error in the Funding statement. One of the funding sources was missing from the original published statement. The correct Funding statement appears below. “The research was financed by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the molecular biology thematic program of the Semmelweis University, “MOLORKIV”(TKP2021-EGA-24) to ZP. ZP, RW and LH are supported by funds of the EU MSCA project CORVOS 860044. The research was further funded by the Austrian Science Fund (FWF), HOROS W-1253. In addition, the research project (project number: 2020-1.1.6-JÖVŐ-2021-00013 to ZP) was further funded by the Ministry of Culture and Innovation with support from the National Research Development and Innovation Fund under the Investment into Future call (2020-1.1.6-JÖVŐ) programme.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: early complement activation, classical pathway activation, lectin pathway activation, C1-INH complexes, assay development and validation, C1s/C1-INH complex, MASP-1/C1-INH complex
Citation: Hurler L, Toonen EJM, Kajdácsi E, van Bree B, Brandwijk RJMGE, de Bruin W, Lyons PA, Bergamaschi L, Cambridge Institute of Therapeutic Immunology Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, Sinkovits G, Cervenak L, Würzner R and Prohászka Z (2025) Corrigendum: Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs. Front. Immunol. 16:1561850. doi: 10.3389/fimmu.2025.1561850
Received: 16 January 2025; Accepted: 28 January 2025;
Published: 12 February 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Hurler, Toonen, Kajdácsi, van Bree, Brandwijk, de Bruin, Lyons, Bergamaschi, Cambridge Institute of Therapeutic Immunology Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, Sinkovits, Cervenak, Würzner and Prohászka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zoltán Prohászka, cHJvaGFzemthLnpvbHRhbkBtZWQuc2VtbWVsd2Vpcy11bml2Lmh1